AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2869210 — intervention group
Group type: COMPARATOR
Intervention: Control (preimmunisation titres)
Number of subjects: 13
Study 30975047 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth care solution (Telekit)
Number of subjects: 299
Study 30975047 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 299
Study 29427355 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 97
Study 29427355 — intervention group
Group type: COMPARATOR
Intervention: Observational arm
Number of subjects: 97
Study 26536214 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 0
Study 26536214 — intervention group
Group type: COMPARATOR
Intervention: Control (no RIC)
Number of subjects: 0
Study 24114969 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg once daily
Number of subjects: 528
Study 24114969 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 500/50 μg twice daily
Number of subjects: 528
Study 22422352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration (tablet)
Number of subjects: 178
Study 22422352 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration (injection)
Number of subjects: 178
Study 19744283 — intervention group
Group type: EXPERIMENTAL
Intervention: ab initio calcineurin inhibitor-based monotherapy immunosuppression
Number of subjects: 203
Study 17596275 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert support group
Number of subjects: 78
Study 17596275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 16229636 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive glucose measurements using tissue modulated Raman spectroscopy
Number of subjects: 49
Study 16229636 — intervention group
Group type: COMPARATOR
Intervention: Fingerstick glucose measurements (HemoCue)
Number of subjects: 49
Study 12117082 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 50
Study 12117082 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.2% ophthalmic suspension
Number of subjects: 50
Study 12117082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10195537 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of mepivacaine 1% with 100 mg of tramadol (Group B)
Number of subjects: 60
Study 10195537 — intervention group
Group type: COMPARATOR
Intervention: 40 mL of mepivacaine 1% (Group A)
Number of subjects: 60
Study 10195537 — intervention group
Group type: COMPARATOR
Intervention: 40 mL of mepivacaine 1% with 2 mL of isotonic sodium chloride solution and 100 mg of tramadol i.v. (Group C)
Number of subjects: 60
Study 7782256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin calcium ointment, intranasally bid for 5 days
Number of subjects: 68
Study 7782256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 7782256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin calcium ointment
Number of subjects: 68
Study 2331280 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and self‐palpation (EP)
Number of subjects: 76
Study 2331280 — intervention group
Group type: COMPARATOR
Intervention: Education and an ambulatory monitor (EM)
Number of subjects: 76
Study 7416559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual food drops (egg, corn, milk, yeast)
Number of subjects: 15
Study 7416559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31994511 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40, 80, 120 or 160 mg/d)
Number of subjects: 230
Study 29233028 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg liothyronine via nasogastric tube after gastric lavage, in the first 6 h of poisoning
Number of subjects: 24
Study 29233028 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment of AlP poisoning (control group)
Number of subjects: 24
Study 26110350 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric overload training (6-week squat training in the flywheel)
Number of subjects: 20
Study 26110350 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (control)
Number of subjects: 20
Study 24060707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg
Number of subjects: 44
Study 24060707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 44
Study 24060707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 44
Study 24060707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 180 mg
Number of subjects: 44
Study 24060707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22610936 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting and Planning (GAP)
Number of subjects: 55
Study 22610936 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 55
Study 19282040 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy (HT)
Number of subjects: 70
Study 19282040 — intervention group
Group type: COMPARATOR
Intervention: Conventional gyms (no-hydrotherapy group=NHTG)
Number of subjects: 70
Study 17868675 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical closure of obstetric fistulas (vaginal, abdominal, and combined approaches)
Number of subjects: 0
Study 17868675 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged bladder drainage
Number of subjects: 0
Study 17868675 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal operative repair of mature fistulas
Number of subjects: 0
Study 16032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial-nerve stimulation
Number of subjects: 120
Study 16032582 — intervention group
Group type: COMPARATOR
Intervention: Median-nerve stimulation
Number of subjects: 120
Study 16032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial-nerve plus musculocutaneous-nerve stimulation
Number of subjects: 120
Study 16032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-nerve stimulation
Number of subjects: 120
Study 12383144 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication improvement program (usual care with intervention)
Number of subjects: 259
Study 12383144 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 259
Study 10619540 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (six sessions before exposure)
Number of subjects: 20
Study 10619540 — intervention group
Group type: COMPARATOR
Intervention: No relaxation training (control group)
Number of subjects: 20
Study 8909433 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (L-leucine 12 g, L-isoleucine 8 g, L-valine 6.4 g daily)
Number of subjects: 95
Study 8909433 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threonine (4 g daily) with pyridoxal phosphate (160 mg daily)
Number of subjects: 95
Study 8909433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 8909433 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA and L-threonine
Number of subjects: 95
Study 8909433 — intervention group
Group type: COMPARATOR
Intervention: BCAA, L-threonine, and placebo
Number of subjects: 95
Study 1749780 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly mixed glass ionomer (Ketac‐Fil)
Number of subjects: 10
Study 1749780 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially aged glass ionomer (Ketac‐Fil)
Number of subjects: 10
Study 1749780 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly mixed silver glass ionomer (Ketac‐Silver)
Number of subjects: 10
Study 1749780 — intervention group
Group type: COMPARATOR
Intervention: Light‐cured hybrid composite (Valux)
Number of subjects: 10
Study 6749576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (1000 mg/day)
Number of subjects: 30
Study 6749576 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg/day)
Number of subjects: 30
Study 31070770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node navigation surgery (SNNS)
Number of subjects: 0
Study 31070770 — intervention group
Group type: COMPARATOR
Intervention: Systematic lymphadenectomy
Number of subjects: 0
Study 29402701 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and systematic integration of palliative care
Number of subjects: 186
Study 29402701 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological care
Number of subjects: 186
Study 26918662 — intervention group
Group type: EXPERIMENTAL
Intervention: BNX-RDT
Number of subjects: 566
Study 26918662 — intervention group
Group type: COMPARATOR
Intervention: BNX film
Number of subjects: 566
Study 23958793 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (150mg per day for 30 days)
Number of subjects: 11
Study 23958793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 22673600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Number of subjects: 127
Study 22673600 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 127
Study 20456285 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention (1 day of didactic lectures, six 3-hour educational outreach visits, and an electronic reminder during drug prescribing)
Number of subjects: 232
Study 20456285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 232
Study 17508623 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Flossing Device (AF)
Number of subjects: 76
Study 17508623 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 76
Study 17508623 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Flossing (M)
Number of subjects: 76
Study 16213238 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group walking on a treadmill for 15 minutes, 3 times a week for 8 weeks while matching step-to-step reaction forces.
Number of subjects: 28
Study 16213238 — intervention group
Group type: EXPERIMENTAL
Intervention: No-feedback group walking for equal time without feedback.
Number of subjects: 28
Study 16213238 — intervention group
Group type: COMPARATOR
Intervention: Control group did not train.
Number of subjects: 28
Study 11834122 — intervention group
Group type: EXPERIMENTAL
Intervention: Access bar and water
Number of subjects: 12
Study 11834122 — intervention group
Group type: COMPARATOR
Intervention: Uncle Tobys Peanut Butter Muesli Bar and water
Number of subjects: 12
Study 11834122 — intervention group
Group type: COMPARATOR
Intervention: Crystal Light
Number of subjects: 12
Study 10075382 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet
Number of subjects: 70
Study 10075382 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet
Number of subjects: 70
Study 7733042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar fortified with 1 g FeNaEDTA and 15 mg retinol as retinyl palmitate/kg
Number of subjects: 17000
Study 7733042 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A‐fortified sugar (control)
Number of subjects: 17000
Study 2139303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study 7164001 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 mg/kg)
Number of subjects: 19
Study 7164001 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 19
Study 31204836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 85
Study 31204836 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT integrated with motivational interviewing
Number of subjects: 85
Study 30726693 — intervention group
Group type: COMPARATOR
Intervention: Givosiran (0.35 or 1.0 mg/kg) once-monthly injections in part B
Number of subjects: 40
Study 30726693 — intervention group
Group type: COMPARATOR
Intervention: Givosiran (2.5 or 5.0 mg/kg) once-monthly injections in part C
Number of subjects: 40
Study 30726693 — intervention group
Group type: COMPARATOR
Intervention: Givosiran (0.035, 0.10, 0.35, 1.0, or 2.5 mg/kg) single subcutaneous injection in part A
Number of subjects: 40
Study 30726693 — intervention group
Group type: COMPARATOR
Intervention: Givosiran (once-monthly or once-quarterly injections in part C)
Number of subjects: 40
Study 27919300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial pulsed electromagnetic fields (PEMF) for 6 weeks
Number of subjects: 39
Study 27919300 — intervention group
Group type: COMPARATOR
Intervention: Placebo PEMF (no stimulation) for 6 weeks
Number of subjects: 39
Study 26823793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cyclophosphamide (500 mg/m2 pemetrexed + 20 mg/kg cyclophosphamide)
Number of subjects: 62
Study 26823793 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed monotherapy (500 mg/m2 pemetrexed)
Number of subjects: 62
Study 25549103 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of propranolol HCl administered orally after memory reactivation phase.
Number of subjects: 0
Study 25549103 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 0
Study 22884505 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance dose)
Number of subjects: 596
Study 22884505 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (fixed dose of 600 mg)
Number of subjects: 596
Study 22884505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 596
Study 19482490 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted glenoid implantation
Number of subjects: 16
Study 19482490 — intervention group
Group type: COMPARATOR
Intervention: Traditional glenoid implantation
Number of subjects: 16
Study 17623343 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (T)
Number of subjects: 0
Study 17623343 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study 17334935 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine upstream tirofiban
Number of subjects: 548
Study 17334935 — intervention group
Group type: COMPARATOR
Intervention: Selective down stream tirofiban
Number of subjects: 548
Study 15233825 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression started 3 days before transplantation (n = 30)
Number of subjects: 60
Study 15233825 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppression started on the first day after surgery (n = 30)
Number of subjects: 60
Study 10601401 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke family care worker intervention
Number of subjects: 372
Study 9187434 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVmP-VB (cyclophosphamide, hydroxorubicin, Vm-26, prednisone + vincristine and bleomycin)
Number of subjects: 140
Study 9187434 — intervention group
Group type: COMPARATOR
Intervention: CHVmP (cyclophosphamide, hydroxorubicin, Vm-26, prednisone)
Number of subjects: 140
Study 9187434 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVmP-VB
Number of subjects: 140
Study 9187434 — intervention group
Group type: COMPARATOR
Intervention: CHVmP
Number of subjects: 140
Study 9187434 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVmP-VB and CHVmP
Number of subjects: 140
Study 1336998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose arginine-vasopressin (AVP)
Number of subjects: 0
Study 1336998 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of arginine-vasopressin (AVP)
Number of subjects: 0
Study 1336998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4007463 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheterisation (SC)
Number of subjects: 157
Study 4007463 — intervention group
Group type: COMPARATOR
Intervention: Transurethral catheterisation (TC)
Number of subjects: 157
Study 29140227 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 3384
Study 29140227 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 3384
Study 29140227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3384
Study 27582239 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 200
Study 27582239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 200
Study 25660493 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily)
Number of subjects: 47
Study 25660493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 23599642 — intervention group
Group type: EXPERIMENTAL
Intervention: BB536-H (5 × 10¹⁰ cfu)
Number of subjects: 206
Study 23599642 — intervention group
Group type: EXPERIMENTAL
Intervention: BB536-L (2.5 × 10¹⁰ cfu)
Number of subjects: 206
Study 23599642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 23599642 — intervention group
Group type: EXPERIMENTAL
Intervention: BB536-L and BB536-H
Number of subjects: 206
Study 21570111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and fluorouracil (group B)
Number of subjects: 459
Study 21570111 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (group C)
Number of subjects: 459
Study 21570111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (group B)
Number of subjects: 459
Study 19324253 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive cilostazol (triple group; n = 30)
Number of subjects: 60
Study 19324253 — intervention group
Group type: COMPARATOR
Intervention: High maintenance dose clopidogrel (high-MD group; n = 30)
Number of subjects: 60
Study 19324253 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive cilostazol (triple group)
Number of subjects: 60
Study 19324253 — intervention group
Group type: COMPARATOR
Intervention: High maintenance dose clopidogrel (high-MD group)
Number of subjects: 60
Study 16964595 — intervention group
Group type: EXPERIMENTAL
Intervention: HB‐AS04 vaccine (2 doses)
Number of subjects: 93
Study 16964595 — intervention group
Group type: COMPARATOR
Intervention: Licensed HB vaccine (3 double doses)
Number of subjects: 93
Study 16964595 — intervention group
Group type: EXPERIMENTAL
Intervention: HB‐AS04 vaccine (in subjects who did not undergo liver transplantation before booster)
Number of subjects: 93
Study 16964595 — intervention group
Group type: COMPARATOR
Intervention: Licensed HB vaccine (in subjects who did not undergo liver transplantation before booster)
Number of subjects: 93
Study 15476476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus/MMF/P
Number of subjects: 61
Study 15476476 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine/MMF/P
Number of subjects: 61
Study 11794893 — intervention group
Group type: EXPERIMENTAL
Intervention: Short anticoagulant course (3 months) for patients with temporary risk factors
Number of subjects: 0
Study 11794893 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer anticoagulant course (6 months at least) for cases with permanent risk factors or idiopathic venous thromboembolism
Number of subjects: 0
Study 11794893 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week treatment for isolated calf vein thrombosis
Number of subjects: 0
Study 11794893 — intervention group
Group type: EXPERIMENTAL
Intervention: Long course of oral anticoagulant therapy
Number of subjects: 0
Study 11794893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- or fixed-dose oral anticoagulation
Number of subjects: 0
Study 9862108 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen dressing
Number of subjects: 20
Study 9862108 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane dressing
Number of subjects: 20
Study 7832080 — intervention group
Group type: EXPERIMENTAL
Intervention: Sairei-to
Number of subjects: 167
Study 3060191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.15 mg kg‐1, intramuscular)
Number of subjects: 12
Study 3060191 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (oral, twice daily for 2 days)
Number of subjects: 12
Study 31034303 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual kayak paddling (VKP) exercise for 60 min twice a week for 6 weeks
Number of subjects: 60
Study 31034303 — intervention group
Group type: COMPARATOR
Intervention: Control group performing home exercises
Number of subjects: 60
Study 28237861 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06291874 15mg once daily for 28 days
Number of subjects: 172
Study 28237861 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06291874 35mg once daily for 28 days
Number of subjects: 172
Study 28237861 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06291874 75mg once daily for 28 days
Number of subjects: 172
Study 28237861 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06291874 150mg once daily for 28 days
Number of subjects: 172
Study 28237861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 28237861 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06291874
Number of subjects: 172
Study 25782738 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation for painful bone metastases
Number of subjects: 119
Study 24022532 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral antibiotics (500 mg of kanamycin and 500 mg of metronidazole) plus intravenous antimicrobial prophylaxis
Number of subjects: 200
Study 24022532 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antimicrobial prophylaxis alone
Number of subjects: 200
Study 21500960 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to visually fixate a video image in response to an internal cue (opening own mouth)
Number of subjects: 173
Study 21500960 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to visually fixate a video image in response to an external cue (seeing a face open its mouth)
Number of subjects: 173
Study 21500960 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to visually fixate a video image in response to both internal and external cues
Number of subjects: 173
Study 18344842 — intervention group
Group type: COMPARATOR
Intervention: Short-term MV (n = 40)
Number of subjects: 54
Study 18344842 — intervention group
Group type: COMPARATOR
Intervention: Long-term MV (n = 10)
Number of subjects: 54
Study 18344842 — intervention group
Group type: COMPARATOR
Intervention: Unilateral VAP (n = 4)
Number of subjects: 54